HARBIN GLORIA PHARMACEUTICALS Balance Sheet Health
Financial Health criteria checks 4/6
HARBIN GLORIA PHARMACEUTICALS has a total shareholder equity of CN¥1.9B and total debt of CN¥44.5M, which brings its debt-to-equity ratio to 2.3%. Its total assets and total liabilities are CN¥2.8B and CN¥912.5M respectively. HARBIN GLORIA PHARMACEUTICALS's EBIT is CN¥136.1M making its interest coverage ratio 1.5. It has cash and short-term investments of CN¥468.7M.
Key information
2.3%
Debt to equity ratio
CN¥44.54m
Debt
| Interest coverage ratio | 1.5x |
| Cash | CN¥468.71m |
| Equity | CN¥1.91b |
| Total liabilities | CN¥912.54m |
| Total assets | CN¥2.83b |
Recent financial health updates
Recent updates
Here's Why HARBIN GLORIA PHARMACEUTICALS (SZSE:002437) Can Manage Its Debt Responsibly
Dec 26
HARBIN GLORIA PHARMACEUTICALS Co., LTD (SZSE:002437) Surges 29% Yet Its Low P/S Is No Reason For Excitement
Nov 08HARBIN GLORIA PHARMACEUTICALS' (SZSE:002437) Solid Earnings May Rest On Weak Foundations
Nov 04Insufficient Growth At HARBIN GLORIA PHARMACEUTICALS Co., LTD (SZSE:002437) Hampers Share Price
Jul 03Why HARBIN GLORIA PHARMACEUTICALS' (SZSE:002437) Earnings Are Better Than They Seem
Apr 22Financial Position Analysis
Short Term Liabilities: 002437's short term assets (CN¥870.4M) do not cover its short term liabilities (CN¥871.9M).
Long Term Liabilities: 002437's short term assets (CN¥870.4M) exceed its long term liabilities (CN¥40.7M).
Debt to Equity History and Analysis
Debt Level: 002437 has more cash than its total debt.
Reducing Debt: 002437's debt to equity ratio has reduced from 63.2% to 2.3% over the past 5 years.
Debt Coverage: 002437's debt is well covered by operating cash flow (600.7%).
Interest Coverage: 002437's interest payments on its debt are not well covered by EBIT (1.5x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 20:33 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HARBIN GLORIA PHARMACEUTICALS Co., LTD is covered by 13 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yalei Yan | Bohai Securities Co., Ltd. |
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Shanshan Li | China Merchants Securities Co. Ltd. |